secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001628280-25-002925
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen posts corporate presentation showing positive retinal gene therapy data
------------------------------------------------------------------------------

- Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).
- LL VA decline at 6 months was lower in treated eyes compared to untreated across multiple study cohorts.
- Presentation features data from cohorts 006-001, 007-001, and 006-004 suggesting consistent treatment benefit.
- Ocugen plans to use this presentation in discussions with investors and analysts on January 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/0001628280-25-002925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/ocgn-20250129.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-002925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer